细胞内细菌的生长是由围绕PKB/AKT1的酶网络控制的
Coenraad Kuijl1, Nigel D L Savage, Marije Marsman
1Division of Tumor Biology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
Nature
|November 30, 2007
概括
新的激酶抑制剂向宿主通路,对抗多药耐药细菌. 这些AKT1抑制剂阻断了细胞内病原体的生长,为抗击沙门氏菌 (Salmonella typhimurium) 和结核菌 (Mycobacterium tuberculosis) 等感染提供了新的策略.
科学领域:
- 微生物学 微生物学
- 细胞生物学 细胞生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 多药耐药 (MDR) 细菌的兴起需要超越传统抗生素的新疗法策略.
- 现有的抗生素主要向细菌通路,使宿主导的方法对细胞内病原体未得到充分探索.
研究的目的:
- 确定宿主特异性点,并开发针对细胞内细菌病原体的新型治疗剂.
- 研究宿主激酶在细菌细胞内生存中的作用,并开发抑制剂以抵消病原体操纵.
主要方法:
- 使用自动化显微镜对人体基因组进行了RNA干扰屏幕,以识别参与沙门氏菌typhimurium细胞内生长的宿主基因酶.
- 利用相互化学遗传学的方法来识别具有抗生素特性的激酶抑制剂及其宿主标.
- 研究了沙门氏菌型菌效应物SopB和其下游通路 (PAK4,AS160-RAB14) 激活AKT1的情况.
主要成果:
- 确定了几种宿主激酶,特别是AKT1 (蛋白激酶B),可以抑制S. typhimurium的细胞内生长.
- 证明AKT1抑制剂有效防止各种细菌的细胞内生长,包括MDR Mycobacterium tuberculosis.
- 阐明了沙门氏菌型菌通过SopB激活AKT1以操纵宿主通路 (动因动态,菌体-溶解体融合) 以实现细胞内生存.
结论:
- 酶抑制剂向宿主通路,特别是AKT1,代表了对抗细胞内病原体的有前途的新类抗生素.
- 针对细菌操纵的宿主信号网络提供了一种可行的策略来克服MDR感染.
- 这项研究为发现宿主导疗法提供了一个框架,通过识别细菌病变发生过程中的关键宿主激酶及其调节剂.
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
cAMP-dependent Protein Kinase Pathways
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
Stringent Response in E. coli
Bacterial growth is closely tied to nutrient availability, with cells proliferating exponentially under favorable conditions and entering a stationary phase when resources become scarce. This transition is mediated by a regulatory mechanism known as the stringent response, which allows bacteria to adapt to nutrient deprivation by modulating gene expression and metabolic activity.During nutrient scarcity, intracellular amino acid levels decline. It results in the accumulation of uncharged tRNAs...
Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...


